SEPTInvestingStart Free

ELVN 10-Q: SEC filing

Enliven Therapeutics

Filed with the SEC on · accession 0001193125-26-449870

ELVN filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. Enliven Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial statements, equity activity, and fair value measurements.

Summary of the filing

Enliven Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial statements, equity activity, and fair value measurements. No single material corporate event is identifiable from the filing.

For details, click here →How to read a 10-Q →

Key details

FilerEnliven Therapeutics, Inc.

✦ Ask GOAX AI about this filing — what it means for ELVN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ELVN?

Click here

Frequently asked questions

What did ELVN file with the SEC on Nov 5, 2026?

ELVN filed a 10-Q (SEC filing). Enliven Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing routine financial statements, equity activity, and fair value measurements. No single material corporate event is identifiable from the filing.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other ELVN SEC filings

Get alerts when ELVN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
ELVN overviewELVN analysisELVN newsLatest SEC filings